Trial Profile
Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Darunavir/ritonavir (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir (Primary) ; Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Raltegravir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Zidovudine (Primary)
- Indications HIV-2 infections
- Focus Therapeutic Use
- Acronyms RESIST-2
- 18 Dec 2021 Results published in the Trials
- 20 Jan 2021 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped:COVID-19 and Funding.
- 17 Jan 2020 Planned primary completion date changed from 1 Jan 2022 to 31 May 2020.